Teneligliptin

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Teneligliptin (20 mg) is a third-generation, highly selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique J-shaped conformation that binds to subsite S1, S2, and S2-extensive pockets of the DPP-4 enzyme, achieving powerful enzyme inhibition (>80% at 24 hours) with a half-life of 24.2 hours. It is eliminated through dual hepatic and renal pathways, allowing standard once-daily dosing across all stages of chronic kidney disease (CKD) without dose adjustments. Indicated for type 2 diabetes mellitus as monotherapy or in combination with other oral antidiabetic agents.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.

Metformin Hydrochloride and Teneligliptin combines an insulin sensitizer with a long-acting peptidomimetic DPP-4 inhibitor. Teneligliptin possesses a unique "J-shaped" chemical structure with five consecutive binding anchors on the DPP-4 enzyme, providing potent and prolonged (>24 hour) incretin stabilization without requiring dose reduction in renal impairment, while metformin controls fasting hyperglycemia. Indicated for type 2 diabetes mellitus in adult patients.